

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/768,872	01/23/2001	Rina Aharoni	60772-PCT-US/JPW/GJG/CSN	3801
75	90 04/22/2003			
John P. White Cooper & Dunham LLP 1185 Avenue of the Americas			EXAMINER	
			DECLOUX, AMY M	
New York, NY 10036			ART UNIT	PAPER NUMBER
			1644.	12
			DATE MAILED: 04/22/2003	[7]

Please find below and/or attached an Office communication concerning this application or proceeding.

	Applicati n N .	Applicant(s)				
		AHARONI ET AL.				
Office Action Summary	09/768,872	Art Unit				
Omoo Modern Gammary	Examiner	1644				
The MAILING DATE of this communication app	Amy M. DeCloux ears on the cover sheet with the					
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on <u>03 F</u>	is action is non-final.					
,—		prosecution as to the merits is				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims						
4) Claim(s) 1-46 is/are pending in the application.						
4a) Of the above claim(s) 5-15,21-31 and 40-46 is/are withdrawn from consideration.						
5)⊠ Claim(s) <u>16-20 and 32-39</u> is/are allowed.						
6)⊠ Claim(s) <u>1-4</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or election requirement.						
Application Papers	_					
9) The specification is objected to by the Examiner. 10) The drawing(s) filed on <u>06 August 2001</u> is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to th						
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14)⊠ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Notice of Draftsperson's Patent Drawing Review (PTO-948) Notice of Draftsperson's Patent Drawing Review (PTO-948) Notice of References Cited (PTO-892)	5) Notice of Informa	ary (PTO-413) Paper No(s) Il Patent Application (PTO-152)				

Application/Control Number: 09/768,872

Art Unit: 1644

DETAILED ACTION

Response to Amendment

Applicant's amendment filed 2-3-03 (Paper No. 16) is acknowledged and has been entered.

Claims 1-46 are pending. Claims 5-15, 21-31 and 40-46 have been withdrawn from consideration. Claims 1-4, 16-20 and 32-39 are under consideration.

In view of said amendment, the 112 second paragraph has been withdrawn.

In view of said amendment which contained a statement that the substitute specification contains no new matter, the substitute specification filed 1-23-01, has been entered.

However the outstanding 102 (f) rejection has been maintained.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(f) he did not himself invent the subject matter sought to be patented.

MAINTAINED Claims 1-4 are rejected under 35 U.S.C. 102(f) because the applicant did not invent the claimed subject matter. The instant specification discloses on page 31 of the substitute specification and page 34 of the originally filed specification that the terpolymer consisting essentially of tyrosine, alanine and lysine randomly polymerized into a polypeptide, wherein said tyrosine is present in a mole fraction of about 0.102, said alanine is present in a mole fraction of about 0.542, and said lysine is present in a mole fraction of about 0.353 was obtained from Teva Pharmaceuticals Industry. It is noted that Teva Pharmaceuticals Industry is not an assignee either. Clarification is required in order to overcome this rejection.

Application/Control Number: 09/768,872

Art Unit: 1644

Response to Arguments

Applicants state that Teva Pharmaceutical Industries is a licensee under the subject application, but applicants have not as of the time of filing said amendment completed their invstigation.

Allowable Subject Matter

Claims 16-20 and 32-39 contain allowable subject material.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy M. DeCloux whose telephone number is 703 306-5821. The examiner can normally be reached on M-F 9:00-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 703 308-3973. The fax phone numbers for the organization where this application or proceeding is assigned are 703 872-9306 for regular communications and 703 872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703 308-0196.

Amy DeCloux, Ph.D. Patent Examiner April 15, 2003 Patrick J. Nolan, Ph.D.
Primary Patent Examiner
Group 1640

Group 1640